Matches in Wikidata for { <http://www.wikidata.org/entity/Q96610322> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q96610322 description "article scientifique publié en 2020" @default.
- Q96610322 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96610322 description "scientific article published on 21 June 2020" @default.
- Q96610322 description "wetenschappelijk artikel" @default.
- Q96610322 description "наукова стаття, опублікована 21 червня 2020" @default.
- Q96610322 name "Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non-inferiority phase III trial" @default.
- Q96610322 name "Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non-inferiority phase III trial" @default.
- Q96610322 type Item @default.
- Q96610322 label "Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non-inferiority phase III trial" @default.
- Q96610322 label "Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non-inferiority phase III trial" @default.
- Q96610322 prefLabel "Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non-inferiority phase III trial" @default.
- Q96610322 prefLabel "Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non-inferiority phase III trial" @default.
- Q96610322 P1433 Q96610322-41206043-4CDA-4272-AB18-C6BDA12A256B @default.
- Q96610322 P1476 Q96610322-81E2B9D3-D7C2-4959-8391-D402A5C82901 @default.
- Q96610322 P2093 Q96610322-0994699D-C490-4DF8-8AF7-E796A2D1F0CA @default.
- Q96610322 P2093 Q96610322-167782DD-2F4E-4FEA-972B-2C407620B46C @default.
- Q96610322 P2093 Q96610322-523C9477-9337-43AB-8FF7-DC5315F40CE8 @default.
- Q96610322 P2093 Q96610322-A1AD13FE-EAE9-466D-A0EB-8465414653CF @default.
- Q96610322 P304 Q96610322-439E4788-66EA-4618-BD56-2D3DBF9F9175 @default.
- Q96610322 P31 Q96610322-44C82EF0-4FEB-445B-977C-D883D5E8091B @default.
- Q96610322 P356 Q96610322-8D541F16-4447-4603-B343-76430A2D0FF2 @default.
- Q96610322 P50 Q96610322-CAD887DC-6FB7-4BFE-8D02-08C746628DB5 @default.
- Q96610322 P50 Q96610322-E2B3C091-54F3-4C7C-93A5-BBAF60547856 @default.
- Q96610322 P577 Q96610322-C0103084-99A7-414A-931A-EBDA0089EB17 @default.
- Q96610322 P698 Q96610322-F9E4CB50-1E97-407B-B7DE-1D8FDC0CA91E @default.
- Q96610322 P921 Q96610322-9F6B4ACC-EB0B-48C7-93B2-C36932B18C9D @default.
- Q96610322 P921 Q96610322-FC29AA53-6A6B-4226-83E3-9712EB063DD1 @default.
- Q96610322 P356 ECC.13245 @default.
- Q96610322 P698 32567124 @default.
- Q96610322 P1433 Q5412710 @default.
- Q96610322 P1476 "Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non-inferiority phase III trial" @default.
- Q96610322 P2093 "Hongyu Zhang" @default.
- Q96610322 P2093 "Pierre Nicolas" @default.
- Q96610322 P2093 "Qingyuan Zhang" @default.
- Q96610322 P2093 "Tulla Spinelli" @default.
- Q96610322 P304 "e13245" @default.
- Q96610322 P31 Q13442814 @default.
- Q96610322 P356 "10.1111/ECC.13245" @default.
- Q96610322 P50 Q88018392 @default.
- Q96610322 P50 Q92313167 @default.
- Q96610322 P577 "2020-06-21T00:00:00Z" @default.
- Q96610322 P698 "32567124" @default.
- Q96610322 P921 Q419841 @default.
- Q96610322 P921 Q42824827 @default.